Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

Abstract Background At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemming from mechanisms of resistance particularly the nuclear cycling of EGF...

Full description

Bibliographic Details
Main Authors: Brooke N. McKnight, Seongho Kim, Julie L. Boerner, Nerissa T. Viola
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Breast Cancer Research
Subjects:
Nuclear EGFR translocation
EGFR PET imaging
Triple negative breast cancer
Src
Dasatinib
Online Access:http://link.springer.com/article/10.1186/s13058-020-01270-1

Internet

http://link.springer.com/article/10.1186/s13058-020-01270-1

Similar Items